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Abstract
Introduction: Activated partial thromboplastin time (aPTT) is determined and reported as clotting time in seconds aPTT(s), but it is presumed that 
reporting results as patient-to-normal clotting time ratio, aPTT(r), could minimize within-laboratory variability. The aim of study was to investigate 
differences in reporting aPTT results that can affect comparability of the results among Croatian laboratories and suggest further steps for its har-
monization. 
Materials and methods: The questionnaire on aPTT reporting practice was distributed to 83 laboratories through Survey Monkey application in 
March 2019 as the part of the first regular round of Croatian Centre for Quality Assessment in Laboratory Medicine proficiency testing. 
Results: The survey response rate was 0.49. Majority of laboratories report aPTT results as both, seconds and ratio. Participants reported use of 23 
different aPTT(s) reference intervals along with 17 different combinations of reagent/coagulometer and 25 aPTT(s) denominators of different origin 
for aPTT(r) calculation. Despite the same aPTT(s) results, the use of different denominators caused a dispersion of aPTT(r) results that can lead to 
exceeding external quality assessment performance criteria of 7%, particularly when results were compared for the same reagent group only. By 
applying aPTT(s) reference interval mean as denominator for calculation of aPTT(r) reference interval better concordance to harmonized one was 
obtained (17 vs. 27; χ2 = 3.972; P = 0.046).
Conclusion: In order to improve comparability of the results, laboratories are advised to use mean of aPTT(s) reference interval as denominator for 
aPTT(r) calculation. Type of coagulometer need to be considered when evaluating aPTT proficiency test results and its currently acceptable limit of 
performance evaluated accordingly.
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Introduction
Activated partial thromboplastin time (aPTT) is a 
coagulation screening assay that estimates the ac-
tivity of the intrinsic and common coagulation 
pathway. The assay is used to screen for coagula-
tion factor deficiency, monitor unfractionated 
heparin (UFH) therapy and detect the presence of 
lupus anticoagulant (LA) (1). Responsiveness of 
commercially available aPTT reagents on these 
pathophysiological conditions is different as rea-
gents contain different types and concentrations 
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of activators and phospholipids (2). Besides, results 
are highly dependent on the combination of rea-
gent and coagulometer in use, making results 
comparison difficult. Therefore, it is not surprising 
that there is still no global assay standardization.
Activated partial thromboplastin time is deter-
mined and reported as clotting time in seconds 
(aPTT(s)). Reporting of the results as aPTT ratio 
(aPTT(r)) of patient-to-normal clotting time is often 
used in terms of improving comparability of the 
results between different laboratories, especially 
for UFH dose-adjustment or laboratory diagnosis 
of LA (3). Although it is presumed that reporting 
the aPTT(r) has an advantage in reducing within-
laboratory variability, manufacturers usually do 
not provide complete information for calculation 
of aPTT(r) (4). What is considered as “normal” clot-
ting time in patient-to-normal clotting time calcu-
lation usually is not defined (3,4).
In 2005, Croatian Chamber of Medical Biochemists 
(CCMB) recommended reporting of aPTT as ratio, 
with a harmonized reference interval of 0.8-1.2 (5). 
As a sequel to it, in 2006, Commission for External 
Quality Assessment of the Croatian Society of Bio-
chemists (predecessor of Croatian Centre for Quali-
ty Assessment in Laboratory Medicine, CROQALM), 
instructed laboratories to report aPTT(r) along with 
aPTT(s), and specified that it should be calculated 
by dividing the aPTT(s) result with the mean value 
of reference interval that laboratories use for aPTT(s) 
(6). CROQALM assesses performance of both, 
aPTT(s) and aPTT(r). Reporting of the results in both 
ways was also recommended in recently published 
national guidelines (7). According to literature, dif-
ferent external quality assessment (EQA) providers 
assess performance of aPTT in seconds, ratio or in 
both ways, applying quite different acceptable lim-
its of performance, ranging from 15 to 25% (8,9). Ac-
ceptable bias of 7% for aPTT result assessment, 
used by CROQALM from 2017, originates from bio-
logical variability database (10,11). Thus, in addition 
to lack of standardization of aPTT assay as well as 
result reporting there is also no consensus on aPTT 
performance criteria.
The aim of study was to investigate differences in 
reporting aPTT results that can affect comparabili-
ty of the results among Croatian laboratories and 
suggest further steps for its harmonization. 
Materials and methods
Questionnaire design
The Working Group for Laboratory Coagulation 
(WGLC) operating within the Committee for scien-
tific and professional development of the Croatian 
Society of Medical Biochemistry and Laboratory 
Medicine (CSMBLM), in cooperation with the CRO-
QALM created a questionnaire that was distribut-
ed to laboratories performing aPTT assay through 
Survey Monkey application (SurveyMonkey Inc., 
Palo Alto, California, USA) in March 2019 as the part 
of the first regular CROQALM proficiency testing 
round. Participation in the survey was voluntary. 
The questionnaire comprised 9 questions on: ref-
erence intervals for aPTT(s) and aPTT(r), detailed 
data on population used for the determination of 
reference interval provided by the manufacturer, 
values used to calculate aPTT(r) and coefficients of 
variation (CV) on normal and pathological internal 
commercial control levels at last month (Supple-
ment 1). Statements were created by all authors 
and reflected personal impression about the most 
problematic issues related to the comparability of 
aPTT results. The survey was entitled as Question-
naire of WGLC and it was part of the Module 4 (htt-
ps://www.surveymonkey.com/r/PXL6QKP). Addi-
tional data collected from the CROQALM for each 
laboratory that responded the survey were the 
combinations of aPTT reagent and coagulometer 
in use. Furthermore, reference guides or assay 
sheets were reviewed in order to complete and 
compare information on reference intervals for 
different combinations of reagent and coagulom-
eter in use.
Statistical analysis
Data for analysis were obtained by counting and 
calculating frequency of answers by using Micro-
soft Excel 2010 (Microsoft, Redmond, Washington, 
USA) program. Results are reported as counts and 
proportions (N<100). A comparison between 
groups was performed by Chi square test. The val-
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ue of P<0.05 was considered statistically signifi-
cant. Data analyses were performed by using sta-
tistical software MedCalc 11.5.1. (MedCalc Soft-
ware, Ostend, Belgium).
Results
In the first round of CROQALM proficiency testing 
in 2019, 83 laboratories reported results for aPTT 
test. After removing duplicate responds from the 
final data processing, 41 surveys were considered 
for the analysis, resulting in the response rate of 
0.49. No additional exclusion criteria were applied.
Reporting of aPTT results
Among all survey participants, 35/41 reported 
aPTT results both as seconds and ratio, 1/41 re-
ported only aPTT(s), whereas 3/41 reported results 
only as aPTT(r).
Reference intervals - aPTT(s)
In total, 39 laboratories declared the use of 23 differ-
ent reference intervals for aPTT(s) along with 17 dif-
ferent combinations of coagulometers and aPTT re-
agents (Table 1). For reporting aPTT(s), laboratories 
mainly use reference interval assigned by the man-
ufacturer (N = 22), whereas literature data (N = 12) 
or own reference intervals (N = 4) are less in use. 
Only 22/41 participants responded that manufac-
turers provide information on population used for 
setting up aPTT(s) reference interval. When labora-
tories were asked to specify exact details, 5 labora-
tories stated that only number of subjects is provid-
ed, 14 mean values, 7 median and 10 combinations 
of all the above mentioned. Results related to re-
viewing reference guides and assay sheets revealed 
that in addition to the number of participants used 
to determine aPTT(s) reference interval, both, popu-
lation mean and median aPTT(s) value is given by 
manufacturer for reagent/coagulometer combina-
tion used by 34 survey participants. 
Reference intervals - aPTT(r)
Three different reference intervals for reporting 
aPTT(r) results are in use among survey partici-
pants (Table 1). Most of them reported use of har-
monized reference interval (N = 30) given by 
CCMB, but for the calculation of aPTT(r) even 25 
different aPTT(s) values from different sources 
were listed. Mean or median value of the popula-
tion for which reference interval was established is 
used by 11 and 10 participants, respectively, 
whereas the mean of the reference interval in use 
by 17 participants. 
Reported aPTT(s) reference interval limits were di-
vided by the denominator that participants use for 
aPTT(r) calculation in order to check if aPTT(r) ref-
erence interval limits used by laboratories are 
aligned and compatible with the harmonized in-
terval. Compared to harmonized interval a wider 
range of aPTT(r) limits (0.7 to 1.4) was obtained. 
Results revealed that 17 aPTT(r) reference intervals 
are completely in concordance to harmonized ref-
erence interval (Table 1). However, by using the 
aPTT(s) reference interval mean as denominator, a 
significant increase in aPTT(r) concordant refer-
ence intervals was obtained (N = 27; χ2 = 3.972; P = 
0.046) (Table 1).
An example of aberration obtained by applying 
different denominators (mean, median and mean 
of reference interval) is given in Table 2.
Comparability between laboratories 
In the first round of CROQALM proficiency testing 
in 2019, the provider calculated and reported re-
sults for experimental groups with more than five 
participants, depending on aPTT reagents in use 
for normal plasma range. Obtained results of CVs 
in groups that use Siemens Actin FS (N = 62), Sie-
mens Pathromtin SL (N = 5) and Stago STA Cephas-
creen (N = 7) were 5.4%, 4.2% and 2.2%, respec-
tively. Thus, these laboratories successfully meet 
criteria of 7% for aPTT(s) and the final conclusion 
was that 87-100% participants successfully com-
pleted the cycle. Results were not assessed accord-
ing to type of analyser in use.
Among all participants, 33/41 laboratories report-
ed analytical CV for aPTT(s) of internal control sam-
ples, obtained for a month prior to the proficiency 
testing cycle, from 1.2 to 7.0% at the pathological 
control level, and 36 laboratories reported CVs at 
normal level from 1.1 to 10.1%. Also, 5 of 41 labora-
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Survey results: data reported by laboratories Calculated data
Manufacturer Reagent Coagulometer in use N
Reference 
interval 



























22.0-33.0 28.0 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-32.0 26.8 M-Median 0.8-1.2 0.9-1.2 0.8-1.2
24.0-33.0 28.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-32.0 26.8 M-Median 0.8-1.2 0.9-1.2 0.8-1.2
23.0-32.0 27.5 Mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-32.0 27.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-32.0 27.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-32.0 27.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
23.0-31.9 27.45 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
21.8-32.6 26.8 M-Median 0.8-1.2 0.8-1.2 0.8-1.2
BFT II 5
lab does not 
report seconds 24.5 M-mean 0.8-1.2 0.9-1.2 0.9-1.1
23.0-31.9 27.45 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
22.4-29.3 26.2 M-mean 0.8-1.2 0.9-1.1 0.9-1.1
24.3-35.0 29.6 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
22.4-29.3 26.2 M-mean 0.8-1.2 0.9-1.1 0.9-1.1
CA-500 3
22.0-28.0 24.7 M-Median 0.8-1.2 0.9-1.1 0.9-1.1
22.0-37.0 25.5 M-Median 0.8-1.2 0.9-1.5 0.8-1.2
22.0-28.0 25.0 M-Median 0.8-1.2 0.9-1.1 0.9-1.1
CA-560 6
21.8-28.0 24.6 M-Median 0.8-1.2 0.9-1.1 0.9-1.1
21.8-28.0 25.6 M-mean 0.8-1.2 0.9-1.1 0.9-1.1
21.8-28.0 24.0 M-mean 0.8-1.0 0.9-1.2 0.9-1.1
21.8 - 28.0 24.8 M-mean 0.8-1.2 0.9-1.1 0.9-1.1
21.8-28.0 24.8 M-mean 0.8-1.2 0.9-1.1 0.9-1.1
23.0-33.0 28.0 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
CA-620 1 lab does not report seconds 24.6 M-Median 0.8-1.2 0.9-1.2 0.9-1.1
CA-660 2
22.0-28.0 25.0 RI-mean 0.8-1.2 0.9-1.1 0.9-1.1
24.0-33.0 28.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
CS 2000i 2
21.6-28.7 25.2 RI-mean 0.9-1.1 0.9-1.1 0.9-1.1
22.0-33.0 24.2 M-mean 0.8-1.2 0.9-1.4 0.8-1.2
CS-2500 1
25-60 (< 5 days)
32-50 (6 d-3m)
28-43 (3-6 m) 
23-36 (> 6 m) 26.6 RI-mean 0.9-1.4 0.9-1.4
Siemens Pathromtin SL
BFT II 1 22.1-28.1 34.1 M-Median 0.8-1.2 0.8-1.2 0.8-1.2
BCS XP 1 25.0-40.0 32.5 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2
CA-660 1 21.0-33.0
lab do not 
report 
aPTT(r)
NA NA 0.8-1.2 0.8-1.2
Table 1. Combination of aPTT reagents, different coagulometers and reference intervals in use among survey participants
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STA Satellite 1 22.0-36.0 32.4 Manufacturer value 0.8-1.2 0.7-1.0 0.8-1.2
STA Compact 
Max 1 24.0-34.0 32.7 M-mean 0.8-1.2 0.7-1.1 0.8-1.2
APTT–
automate STA Satellite 1 25.0-38.0 29.2 M-mean 0.8-1.2 0.9-1.3 0.8-1.2
Sclavo 
Diagnostics Sclavo aPTT S CA-500 1 23.0-35.0 29.0 RI-mean 0.8-1.2 0.8-1.2 0.8-1.2




lab does not 




21.8-32.6 24.7 RI-mean 0.9-1.1 0.9-1.2 0.8-1.2
Not stated 26.0-36.0 29.8 Not given Not given 0.8-1.2 0.8-1.2
N - number of  laboratories. aPTT(s) - activated partial thromboplastin time reported in seconds. aPTT(r) - activated partial 
thromboplastin time reported as ratio. RI - reference interval. M-mean - manufacturer mean. M-Median - manufacturer median. NA 
- not applicable. d -days. m - months. 
A. An example of data on population used to obtain reference interval that is reported in manufacturers reference guide 
for the particular reagent/coagulometer combination:
N Mean Median 5th - 95th percentile
aPTT(s) 111 27.2 26.8 23.0-31.9
B. Calculated mean of aPTT(s) reference interval suggested to be used by manufacturer:
27.45 (rounded to) 27.5
C. Examples of calculation of aPTT(r) reference interval limits by using different denominators that could be obtained 
from manufacturers reference guides:
Denominator is: Value of aPTT(s) 
denominator
aPTT(r) limits obtained from aPTT(s)
Mean 27.2 0.84-1.17 (0.8-1.2)
Median 26.8 0.86-1.19 (0.9-1.2)
Mean of manufacturer reference interval 27.5 0.83-1.16 (0.8-1.2)
aPTT(r) - activated partial thromboplastin time reported as ratio. aPTT(s) - activated partial thromboplastin time reported in 
seconds.
Table 2. An example of calculating aPTT(r) reference interval by using different denominators obtained from manufacturers refer-
ence guides or assay sheets
Table 1. Continued
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tories did not reported CVs as they stated that for 
control material they use the aPTT target values 
are not provided by the manufacturer.
Discussion
The aim of this survey was to investigate factors 
that contribute to differences in reporting aPTT re-
sults among laboratories in Croatia and to investi-
gate between-laboratory comparability improve-
ment. Survey results revealed that laboratories that 
use same combinations of reagent/coagulometer 
for calculation of aPTT(r), often use denominators 
of different origin. Consequently, aPTT(s) and 
aPTT(r) reference intervals in use are not always 
mutually aligned. Use of different denominators for 
calculating aPTT(r) values complicate comparabili-
ty of the results and such dispersion of aPTT(r) re-
sults may lead to failure to meet the EQA perfor-
mance criteria despite the same aPTT(s) results.
This is not surprising as reference guides or package 
inserts mainly report measured mean and/or medi-
an value of aPTT(s) in population used to establish 
provided reference interval, but the mean value of 
the aPTT(s) reference interval is often slightly differ-
ent from the population mean and manufacturer 
instructions for aPTT(r) calculation are mainly vague. 
Our analysis showed that by applying different de-
nominators for the aPTT(r) calculation, different 
aPTT(r) reference limits, often exceeding allowable 
limit of 7% could be generated for the same combi-
nation of reagent and coagulometer in use. 
Furthermore, CROQALM conducts three proficiency 
testing cycles each year, distributing to participants 
two samples at pathological level and one sample 
at the normal level. Although laboratories mainly 
successfully met the criteria at normal level (> 95% 
participants successfully completed the cycles in 
2017, 2018 and first cycle in 2019), only 43-67% labo-
ratories successfully met the criteria of 7% at the 
pathological level (10,11). Survey participants re-
ported wide range of internal quality control of ana-
lytical CVs for aPTT(s) they obtained on their rea-
gent to coagulometer combination in the month 
prior to the first round of proficiency testing in 2019, 
some of which exceeded 7%. As aPTT(s) reference 
interval for the same aPTT reagent differ for differ-
ent analytical systems, it is not uncommon for this 
limit to be exceeded when EQA results are com-
pared for the same reagent group only. Reviewing 
the proficiency testing results for aPTT, obtained by 
other EQA providers, different approach for result 
assessment could be found (8-11). Different provid-
ers assess differently reported results (exclusively as 
seconds or as ratio, or both), and also apply differ-
ent acceptable limits of the performance (8,9). Re-
sults are assessed according to system in use (rea-
gent/coagulometer) and allowable limit is mainly 
set up in between 15 and 25% (8,9). The acceptable 
limit of 7% used by CROQALM originates from bio-
logical variability database and was set up in 2017 
to assess performance of the aPTT results reported 
as both, seconds and ratio (10). The provider re-
ferred it to different aPTT reagents in use, but with-
out taking into consideration combination of the 
reagents and coagulometer. In the study of Olson 
and colleagues, eight different analytical approach-
es were used by eleven EQA organizations that par-
ticipated in the study. Authors concluded that there 
is lack of agreement of pass/fail grading among 
EQA programs for 218 laboratories. Discordance in 
the grading was 17.9% and 11% of normal and pro-
longed aPTT results, respectively (8). Thus, interna-
tional consensus yet needs to be achieved.
To illustrate the impact of coagulometer on aPTT 
results, an example reflecting similar conditions to 
EQA was obtained from a clinical laboratory oper-
ating at three different locations that uses the 
same aPTT reagent on two different types of co-
agulometers is given (Supplement 2). Two times a 
month, the same patient sample is analysed at 
each location. Results obtained by using same rea-
gents, but different coagulometers cannot meet 
the criteria of 7% in comparison to results ob-
tained on the same coagulometers placed on dif-
ferent locations.
This is often problematic not only for aPTT ex-
pressed in seconds, but especially for the results 
expressed as aPTT(r) (Supplement 2). Thus, it could 
be recommended that EQA results should be as-
sessed according to combination of reagent and 
type of coagulometer in use.
Another problem stemming from these compari-
sons is reporting of the aPTT(r) results with differ-
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ent number of decimal places (Supplement 2). Al-
though reporting aPTT(r) at different number of 
decimal places have no clinical significance and 
should be viewed only in the light of uniformity, 
by applying allowable criteria of 7% significant dif-
ferences in the results could be generated. This 
could be problematic especially for accredited lab-
oratories and renewing licence for the assay.
Also, when considering CVs, survey revealed that 
small proportion of laboratories stated not to have 
target aPTT values for internal control sample in 
use. Since problems with aPTT performance could 
be discovered through unacceptable results of the 
regularly scheduled quality control it is important 
to educate these laboratories to introduce internal 
control samples with aPTT target values into eve-
ryday practice. 
Better comparability of results was obtained by 
using the mean of the aPTT(s) reference interval as 
denominator (5). Thus, it could be recommended 
to the laboratories to use the mean of the applied 
reference interval for the calculation of aPTT(r).
The main limitation of the study certainly was the 
survey response rate. Obtained analysis indicated 
certain critical point that might be important for 
optimisation of reporting aPTT results among Cro-
atian laboratories, but extensive research through 
longer period with comprehensive statistical anal-
ysis should be also performed.
However, more uniformity of the aPTT(r) calculation 
is needed. At first, adherence to current recommen-
dations on aPTT results reporting should be im-
proved (6,7). Laboratories are advised to use the 
same denominator for aPTT(r) calculation, prefera-
bly mean of aPTT(s) reference interval. Type of co-
agulometer need to be considered when evaluat-
ing aPTT proficiency test results and its currently ac-
ceptable limit of performance evaluated accordingly. 
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